Coherus Oncology, Inc.
CHRS
$1.13
-$0.04-3.42%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -20.10% | -37.12% | -46.54% | -17.14% | -1.78% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -20.10% | -37.12% | -46.54% | -17.14% | -1.78% |
| Cost of Revenue | -49.68% | -58.86% | -63.62% | 22.49% | 32.21% |
| Gross Profit | 41.16% | 0.23% | -18.91% | -45.82% | -35.91% |
| SG&A Expenses | -19.26% | -26.85% | -31.22% | -26.56% | -20.50% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -25.17% | -34.46% | -38.44% | -12.58% | -10.72% |
| Operating Income | 29.94% | 31.18% | 27.55% | 7.23% | 17.78% |
| Income Before Tax | 36.63% | 29.01% | 22.64% | 1.93% | 8.16% |
| Income Tax Expenses | -- | -- | -- | 100.00% | -- |
| Earnings from Continuing Operations | 36.53% | 28.89% | 22.51% | 1.76% | 8.31% |
| Earnings from Discontinued Operations | 56.67% | -80.83% | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 712.65% | -120.85% | 111.98% | 99.79% | 88.89% |
| EBIT | 29.94% | 31.18% | 27.55% | 7.23% | 17.78% |
| EBITDA | 30.69% | 32.20% | 28.89% | 8.25% | 18.43% |
| EPS Basic | 582.47% | -62.18% | 110.42% | 99.70% | 90.35% |
| Normalized Basic EPS | -45.45% | -35.76% | -17.66% | 35.59% | 41.14% |
| EPS Diluted | 559.65% | -64.15% | 109.22% | 99.51% | 90.07% |
| Normalized Diluted EPS | -45.45% | -35.76% | -17.66% | 35.59% | 41.14% |
| Average Basic Shares Outstanding | 5.90% | 12.72% | 21.94% | 32.74% | 35.55% |
| Average Diluted Shares Outstanding | 5.90% | 12.72% | 21.94% | 32.74% | 35.55% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |